Kornimate/medical-research-clean huggingface dataset:
effect of anti-adhesion barrier on the voice quality after thyroidectomy.

Conditions: Thyroid Nodule; Thyroid Cancer; Voice Disorders

Summary: to determine whether the use of anti-adhesion barrier after thyroid surgery can prevent the voice changes after surgery, using objective voice-related indicators.

* randomized controlled study * including 40 patients in each arm * treatment: anti-adhesion barrier apply on the thyroidectomy space * control: no use of anti-adhesion barrier * primary outcome: vhi-30 (voice handicap index) * secondary outcome: findings from stroboscopy, csl (computerize speech lab) * outcome measurement: preoperative, post-operative 3 months, post-operative 9 months.

Eligibility criteria:
inclusion criteria: * patients undergoing open thyroidectomy for thyroid cancer * patients whose tumor size is less than 4cm * patients who are not suspected of surrounding organ involvement (t4) or metastasis to central lymph nodes in preoperative imaging * patients with no history of voice-related diseases prior to surgery * patients with normal movement of both vocal cords in the preoperative vocal cord examination * patients who consented to the study and obtained consent for the study exclusion criteria: * patients with uncontrolled high blood pressure, diabetes, chronic renal failure, coagulation disease, etc. * history of cardiovascular disease (angina pectoris, heart failure, myocardial infarction, cerebral infarction, cerebral hemorrhage, etc.) * medical history of drug or substance disorder (alcohol, etc.) * patients with diseases related to airways, esophagus, and vocal cords (vocal palsy, vocal cord polyps, etc.) * patients who have already had adhesions in the foreground due to radiation therapy or surgery on the foreground in the past. * patients with a history of keloid or hypertrophic scars * patients planning to perform lateral cervical lymph node dissection * patients with medical thyroid disease, such as graves' disease and thyroid inflammation in need of treatment * pregnant or lactating female patients * other patients who are in charge of clinical trials as unsuitable for participation in the study
post authorization safety study of the pandemic a/h1n1 influenza vaccines in children and adults

Conditions: Influenza; Swine-Origin A/H1N1 Influenza Virus

Summary: this study is designed to assess the safety of the approved and licensed humenza (adjuvanted a/h1n1 pandemic influenza vaccine) and panenza (non-adjuvanted a/h1n1 pandemic influenza vaccine) to meet regulatory requirements for post-marketing safety monitoring. primary objective: to describe the incidence of serious adverse events and adverse events of special interest (aesis) after humenza or panenza administration throughout the study in different age groups. secondary objective: to describe the incidence of non-serious cutaneous allergic reactions after humenza or panenza administration in different age groups up to 21 days after the last vaccination.this study is designed to assess the safety of the approved and licensed humenza (adjuvanted a/h1n1 pandemic influenza vaccine) and panenza (non-adjuvanted a/h1n1 pandemic influenza vaccine) to meet regulatory requirements for post-marketing safety monitoring.

all participants will be vaccinated with study vaccines (1 or 2 doses) at the start of the study and will be monitored for safety for up to 6 months after the last vaccination.

Eligibility criteria:
inclusion criteria : * aged 2 months and above on the day of inclusion * having received humenza or panenza * provision of the contact order form (cof) signed by the participant or the participant's parent(s)/guardians(s) * participant or the participant's parent(s)/legal representative(s) are able to attend all scheduled visits and to comply with all study procedures exclusion criteria : * participant previously vaccinated with another a/h1n1 pandemic vaccine

Keywords: humenza panenza influenza swine-origin influenza a h1n1 virus influenza virus vaccines
comparison of transparent retractable extension device and narrow band imaging on colorectal adenoma detection

Conditions: Colorectal Cancer Screening

Summary: the investigators previously reported that colonoscopy with a transparent retractable extension (tre) device improved the adenoma detection rate without affecting intubation and withdrawal times. on the other hand, colonoscopy using narrow band imaging (nbi) is expected to lead to higher rate s of adenoma detection. the investigators compared the effects of tre device on colorectal adenoma detection with those of nbi.


Eligibility criteria:
exclusion criteria: * age less than 20 years old * pregnant * american society of anesthesiologists class iii and iv * overweight (body weight \> 100 kg) * allergic to the drugs used or its components (soybeans or eggs) * poor bowel preparation * previous colorectal surgical resection

Keywords: colonoscopy hood nbi
reasons for nonattendance inpatient colonoscopy

Conditions: Colonoscopy Nonattendance; Inpatient

Summary: the absence of colonoscopy is a clinical problem that can't be ignored. according to previous studies, the absence rate for outpatient colonoscopy is between 4% and 29%. the aim of this study is to determine the reasons for colonoscopy appointment cancellations among inpatients and to identify the factors associated with colonoscopy nonattendance.


Eligibility criteria:
inclusion criteria: * inpatients older than 18 years. * inpatients undergoing colonoscopy exclusion criteria: * emergency colonoscopy. * pregnant or breastfeeding. * lack of complete data.
pattern of microbial infection in aecopd patients and its sensitivity to antibiotics

Conditions: Acute Exacerbation COPD

Summary: measurement of bacterial species causing aecopd and their sensitivity pattern to antibiotics.

chronic obstructive pulmonary disease (copd) is a major cause of chronic morbidity and mortality worldwide. acute exacerbation is a common problem during the natural course of copd, which is characterized by an increase in the patient's daily symptoms of dyspnea, cough, and/or sputum beyond normal day-to-day variability and severe enough to require an additional therapy. the most common cause of acute exacerbations of copd (aecopd) is an infection of the tracheobronchial tree and air pollution. as many as one-third of aecopd causes are never identified. the microbial aetiology of aecopd includes bacteria and viruses with more than 50% of cases being caused by bacterial infection. the bacterial etiologies of aecopd keep changing from time to time and the choice of antimicrobial depends upon on local prevalence of bacterial etiologies and their resistance pattern. antibiotics are the main form of treatment for aecopd which are often initiated empirically based on healthcare provider's previous experiences , which often lead to the inappropriate use of antibiotics , thereby contributing to antimicrobial resistance. early diagnosis and knowledge of the predominant bacterial etiologies and antimicrobial resistance patterns will also help to correct treatment protocol for the management of aecopd.

Eligibility criteria:
inclusion criteria: * must be at least 18 years of age and less than 80 years of age for both genders * confirmed diagnosis of copd by spirometry * must be an aecopd patient (with increased grade of dyspnea, increased purulence and amount of sputum) and admitted to the chest department or icu * positive sputum culture exclusion criteria: * age less than 18 years old * any associated pulmonary co-morbidity
comparison of the glidescope and macintosh laryngoscope for double lumen endotracheal tube intubation

Conditions: Lung Disease

Summary: patients undergoing chest surgery often require insertion of a breathing tube (double lumen tube) after they are unconscious. the double lumen tube enables the anaesthetist to ventilate (assist breathing) one lung at a time. the other lung is partially deflated to enable enough space for the surgeon to perform the procedure. the breathing tube is inserted with a laryngoscope (blade with a light at the end) so the vocal cords can be seen. this is standard medical practise. two laryngoscopes are commonly used at toronto general hospital to insert the tube. the macintosh laryngoscope has been is use for over 50 years and the glidescope for over 10 years. both devices have been extensively researched for single lumen tubes insertion and found to be very safe and effective. research is limited to say which of the two laryngoscope is the most effective for double lumen tubes.

the glidescope (gvl) has been extensively studied for single lumen tube intubation and found to be a very safe and useful device. it is a particularly useful for patients with difficult airways as it has a camera attached to the blade. despite being used for double lumen tube (dlt) intubations, research of its effectiveness and safety, is lacking. the study aims to determine the speed and safety of the gvl for dlt insertion. this information will assist anaesthetists in choosing the appropriate laryngoscope for dlt intubation of their patients.

Eligibility criteria:
inclusion criteria: population: planned elective lung surgery requiring general anaesthesia with a double lumen endotracheal intubation, signed informed patient consent. exclusion criteria: * previous failed intubation, * history of difficult intubation or anticipated difficult intubation (2 risk factors of mallampati score 3 or greater, * incisor gap \< 3.5cm, thyromental distance \< 6.5cm, * reduced neck extension and flexion), * alternative method of intubation indicated eg rapid sequence intubation, * fibreoptic intubation, * contra-indication to a left double lumen tube eg endobronchial tumor, * significant deviation or compression of the trachea and bronchi., * contraindication to one lung ventilation eg severe hypoxia or pulmonary hypertension, * anticipated difficult bag mask ventilation, * symptomatic gastro-oesophageal reflux, * oral/pharyngeal/laryngeal carcinoma, * loose teeth, * allergy to rocuronium, bmi \> 40.

Keywords: double lumen et intubation laryngoscope lung surgery
incidence and factors associated with double-j urinary stent infection (ijj)

Conditions: Double J Stent

Summary: the aim of the study was to determine the incidence and factors associated with double-j urinary stent infection.


Eligibility criteria:
inclusion criteria: * patients with a double-j stent placement or change in the hospital exclusion criteria: * renal transplants less than one year old
cpap, nutrition & exercise against sleep apnea

Conditions: Sleep Apnea; Overweight and Obesity

Summary: this study evaluates the addition of a comprehensive lifestyle program including dietary management and exercise to continuous positive airway pressure (cpap) therapy in overweighted adults with obstructive sleep apnea. half of the participants will receive cpap therapy while the other half will have diet consultations, nordic walking sessions and cpap.

while the specific impact of obstructive sleep apnea (osa) on quality of life is well established, the impact of cpap therapy on quality of life remains unclear. yet, improving the quality of life of osa patient is one of the main targets of treatment. both exercise and healthy diet are recommended in the management of overweight and obesity. this should improve quality of life as well as comorbidities associated with sleep apnea.

Eligibility criteria:
inclusion criteria: * patients newly diagnosed for obstructive sleep apnea and requiring cpap therapy * bmi\>25and≤40kg/m2 * low physical activity (\< 150 min of mvpa per week) * iah≥15 * able to give informed consent as documented by signature exclusion criteria: * patients already treated for osa or another sleep disorder * required use of supplemental oxygen * active infection, malignancy or chronic inflammatory disorders * more than moderate alcohol use of \> 14 drinks per week * severe depression defined by a bdi \> 30 * surgery within the previous 3 months * known cardiac or pulmonary disease contraindicating exercise training * patient with a bariatric surgery project or already operated * pregnant or lactating women * onset of a severe cardiac disease contraindicating exercise training * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, peripheral functional limitation.

Keywords: obstructive sleep apnea cpap therapy exercise diet quality of life
safety and performance evaluation of the magneto wire

Conditions: Ischemic Stroke

Summary: a prospective, open label single arm feasibility study to evaluate the safety and performance of the magneto wire in patients diagnosed with acute ischemic stroke and planned for thrombectomy procedure.


Eligibility criteria:
inclusion criteria: * acute ischemic stroke within defined timelines. * age 18-85 years old * nihss ≥ 8 * no significant pre-stroke functional disability (mrs ≤ 1) exclusion criteria: * life expectancy of less than 90 days * neurological signs that are rapidly improving prior to or at time of treatment * nihss≥30 or state of coma * ongoing seizure * current use of cocaine or other vasoactive substance * known bleeding diathesis * known hemorrhagic or coagulation deficiency * evidence of active systemic infection * current use of oral anticoagulants inr \> 3 * administration of heparin or novel oral anticoagulants within 48 hours preceding the onset of stroke and have an abnormal aptt at presentation * platelet count \< 50,000/mm3 * glucose \<50 mg/dl (2.8 mmol, 2.6mm) * uncontrolled hypertension (sbp\>185 or dbp\>110) refractory to pharmacological management * known hypersensitivity or allergy to radiographic contrast agents * pregnancy or lactating female * subject already enrolled in a clinical study involving experimental medication or device * ct scan or mri with evidence of acute intracranial hemorrhage, aspect score\<6, mass effect and/or intracranial tumor. * angiographic evidence of carotid dissection, or high grade stenosis that will prevent access to the clot, or cerebral vasculitis, or intracranial stenosis * blood vessel with extreme tortuosity or other conditions preventing the access of the device. * angiographic evidence of carotid dissection, complete cervical carotid occlusions or vasculitis.
premedication for ercp with midazolam or tramadol

Conditions: Chronic Disease

Summary: objective:purpose of this study is to set forth the sedative efficacy and effects on early period cognitive functions of two premedication drugs used for ercp (endoscopic retrograde cholangiopancreatography) methods:this randomized and double blind study was performed with forty (18-70 of age) asa i-iii risk group patients for who elective ercp was planned. cognitive functions of patients were determined by mini-mental test (mmt). 0.5 mg/kg midazolam or 1mg/kg tramadol drop was administered orally before intervention to patients who were randomly divided into two premedication groups. vital signs,bis (bispectral index), mrss (modified ramsay sedation scale), nrs (numeric rating scale ) was evaluated. if mmt (mini-mental test) was ≤ 23 at 60th minute it was considered as cognitive impairment. recovery period, post-procedure state of cognitive function at 60th minute were recorded.

the outcome measures are number of participants with adverse events, and the incidence of postoperative cognitive dysfunction assessed by mmt (mini-mental test) in first 60 minutes.

Eligibility criteria:
inclusion criteria: * this study was conducted in the endoscopy department for forty (18-70 years old) outpatients in asa i-iii risk group were randomized and double blind planned for elective ercp. exclusion criteria: * american society of anesthesiologist (asa) class greater than 3, * morbid obesity, * major organ dysfunction (respiratory, renal and hepatic), * history of drug addiction, * known hypersensitivity for tramadol, midazolam and remifentanil, * mini-mental test (mmt) ≤ 23 or * refusal of the patient.

Keywords: premedication ercp midazolam tramadol cognitive
evaluation of the use of cap in improving the performance of colonoscopy

Conditions: Colonoscopy

Summary: the aim of this study is to compare the colonoscopy success rate, cecal time and polyp detection rate between cap-fitted colonoscopy and conventional colonoscopy.

colonoscopic examination has been used in clinical practice for approximately 40 years. despite the fact that colonoscopy is widely available and is performed by many experienced colonoscopists there are concerns about the quality of colonoscopy as measured by several technical endpoints such as rate of failed caecal intubation and polyp miss rate. a large population-based study revealed 13.1% of colonoscopies failed to reach the cecum. in addition, one large review of back-to-back colonoscopies showed polyp miss rates of 24% for adenoma. one potentially promising technique is cap-assisted colonoscopy. a transparent cap (or "hood") is a simple plastic device that can be attached to the tip of a colonoscope before performing the colonoscopy. several randomized trials from japan have mixed results regarding improved cecal intubation times and polyp detection rates. a recent large study from hong kong showed improved time to cecum but a reduced polyp detection rate. to date there is no large randomized study using the cap in a western population, in whom the colorectal cancer (crc) incidence is known to be higher. we plan to conduct a randomized controlled trial to investigate the usefulness of cap-assisted colonoscopy in a western population.

Eligibility criteria:
inclusion criteria: * all colonoscopy patients referred for colonoscopy at royal prince alfred hospital. exclusion criteria: * prior colonic resection * pregnancy. * severe co-morbidities. * tertiary referral for endo-mucosal resection. * acute surgical conditions such as severe colitis, toxic megacolon, ischemic colitis, acute gastrointestinal bleeding.

Keywords: colonoscopy cap hood cecal intubation time polyp detection rate performance
study to evaluate the response to treatment and safety of 0.03% tacrolimus (fk506) ointment administered in pediatric patients with moderate to severe atopic dermatitis

Conditions: Dermatitis, Atopic

Summary: objective of this study is to further assess the response to treatment and safety of 0.03% tacrolimus (fk506) ointment when used for 6 months in pediatric patients with moderate to severe atopic dermatitis, known to be responsive to topical steroids.

the main phase is 6 month duration, but the follow-up phase up to 12 months will allow the collection of rtt and safety data in a period which will include all seasons in each patient, to account for seasonal variability which strongly affect ad course.

Eligibility criteria:
inclusion criteria: * patient may be male or female of any ethnic group * patient is aged 2 years to 15 years (not having completed his/her 16th birthday) and suffers from moderate to severe atopic dermatitis (rajka/langeland score of at least 4.5). * patient known to be responsive to topical steroids * patient's legal representative has given written informed consent. if the patient is capable of understanding the purposes and risks of the trial written informed consent has been obtained from the patient as well. female patients of childbearing potential must agree to maintain adequate birth control practice during the trial period and during the first four weeks after the end of the study * patient meets the following wash-out criteria: * topical corticosteroids * systemic corticosteroids (for the treatment of ad only) * systemic non-steroidal immunosuppressants (e.g. cyclosporine, methotrexate) * other investigational drugs * light treatments (uva, uvb) * patient has not taken/patient and legal representative agree that the patient does not take for the complete study period any medication or therapy prohibited by the protocol exclusion criteria: * patient has a genetic epidermal barrier defect such as netherton's syndrome or generalised erythroderma * patient is pregnant or breast-feeding * patient has a skin infection on the affected (and to be treated) area * patient has a known hypersensitivity to macrolides in general, to tacrolimus or any excipient of the ointment * patient is simultaneously participating in any other drug trial or less than 28 days have passed between the end of the previous trial and this one * any form of substance abuse (including drug or alcohol abuse), psychiatric disorder or condition which, in the opinion of the investigator, may invalidate the communication with the investigator * patient is known to be hiv positive

Keywords: atopic dermatitis prograf tacrolimus fk506 tacrolimus ointment
the activating consciousness technique (hypnosis) in general practice

Conditions: Anxiety

Summary: anxiety is an emotion considered unpleasant but resulting from a normal phenomenon. it corresponds to an adaptive response to events, to stress and helps to ensure our survival. on the other hand, it becomes embarrassing when it becomes uncontrollable. it can even lead to interfere with activities of daily living. thus, we can speak of anxiety disorder. anxiety disorders are among the most prevalent psychiatric disorders. they are often associated with other comorbidities such as depression, which makes them more difficult to treat and diagnose. different treatments are offered to best treat the patient with anxiety : drug treatment (antidepressants, anxiolytics) ; non-drug (psychotherapy, meditation, cognitive behavioral therapies). the emergence of hypnosis in medical practice in recent years seems to be a technique that can bring benefits to the patient. a review of clinical studies does not seem to find a benefit to hypnosis in anxiety disorders. in contrast, a study in children with school phobia showed the effectiveness of hypnosis. the limits addressed by this review seem to relate to the number of people included in the studies. contrariwise, it has been pointed out that hypnosis can have a beneficial effect in the long term. thus, it seems interesting to deepen this technique in the practice of a general practitioner exercising the activating consciousness technique in anxiety. the study will be composed of patients presenting with anxiety and consulting their general practitioner, with: group 1, patients consulting a doctor not practicing hypnosis versus group 2, patients consulting a doctor practicing hypnosis. during the first consultation and the following 2 consultations scheduled by the general practitioner (spaced 15 days apart), the following data are noted, in addition to the monitoring usually performed by the doctor: 1. covi scale 2. comfort scale 0 to 10 3. management: drugs, tac, others 4. quality of life survey sf36 patients will be called back at 6 months to reassess quality of life (self-administered survey sf 36) the primary endpoint is to evaluated the change of anxiety from inclusion (j0) to 6 months using covi scale in the two different groups. for secondary endpoints, the consumption of drug medicine will be quantified and the quality of life will be measured using quality of life survey sf36.


Eligibility criteria:
inclusion criteria: * male or female over 18 * anxiety patient * patient who can return for consultation regularly and can be reached by phone * patient not opposing participation in study exclusion criteria: - follow-up deemed impossible by the investigator

Keywords: hypnosis anxiety general practice